Treatment satisfaction of patients with advanced non small cell lung cancer receiving platinum based chemotherapy: Results from a prospective cohort study (personal)

Sabine Visser, Mark De Mol, Kiki Cheung, Jermo J. Van Toor, Nico C. Van Walree, Bruno H. Stricker, B.L.. den Oudsten, Joachim G.j.v. Aerts

Research output: Contribution to journalArticleScientificpeer-review

Abstract

Introduction.
In patients with advanced non–small-cell lung cancer, the treatment benefits and risks need to be constantly weighed. We explored patient-reported satisfaction with therapy (SWT) and assessed its value in addition to quality of life (QoL) and adverse events (AEs).

Patients and methods.
In a prospective multicenter cohort study, patients with stage IIIB/IV non–small-cell lung cancer received platinum-pemetrexed chemotherapy. They completed the World Health Organization Quality of Life-BREF (WHOQoL-BREF) and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) before and during chemotherapy. After the last cycle, patients reported on SWT, expectations of therapy, and feelings about side effects (FSE) using the Cancer Therapy Satisfaction Questionnaire. The explained variance (R2) of QoL after treatment by SWT was calculated. Using multivariable linear regression, we examined the association of SWT with patient- and treatment-related variables, FSE, and AEs.

Results.
Eighty-nine patients finished 4 cycles of chemotherapy, 65 of whom completed the Cancer Therapy Satisfaction Questionnaire. Fifty-six patients (86.2%) would probably or definitely decide to undergo the same treatment again, regardless of deterioration or improvement in QoL or a high or low frequency of AEs during chemotherapy. The explained variance of QoL by SWT was greatest for the EORTC QLQ C-30 global health status/QoL scale (R2 = 0.170). Patient age (β = 0.43; 95% confidence interval [CI], 0.05-0.82), FSE (β = 0.17; 95% CI, 0.06-0.29), and tumor response (β = 7.93; 95% CI (1.64 to 14.22)) were independently associated with SWT.

Conclusion.
SWT could provide important supplementary information in addition to QoL assessments and treatment toxicities. Tumor response, older age, and FSE score were associated with better SWT. These insights could affect decision-making during palliative chemotherapy

Original languageEnglish
Pages (from-to)e503-e516
JournalClinical Lung Cancer
Volume19
Issue number4
DOIs
Publication statusPublished - 2018

Fingerprint

Confidence Intervals
Neoplasms
Multicenter Studies
Linear Models
Organizations
Surveys and Questionnaires
Global Health

Keywords

  • BREAST-CANCER
  • CTSQ
  • MAINTENANCE THERAPY
  • NSCLC
  • PATIENTS ATTITUDES
  • PATIENTS PREFERENCES
  • PEMETREXED PLUS CISPLATIN
  • PHASE-III
  • PLACEBO PLUS
  • Palliative chemotherapy
  • QUALITY-OF-LIFE
  • Quality of life
  • SUPPORTIVE CARE
  • Satisfaction with therapy
  • TRIAL

Cite this

Visser, Sabine ; De Mol, Mark ; Cheung, Kiki ; Van Toor, Jermo J. ; Van Walree, Nico C. ; Stricker, Bruno H. ; den Oudsten, B.L.. ; Aerts, Joachim G.j.v. / Treatment satisfaction of patients with advanced non small cell lung cancer receiving platinum based chemotherapy : Results from a prospective cohort study (personal). In: Clinical Lung Cancer. 2018 ; Vol. 19, No. 4. pp. e503-e516.
@article{d7f1adfdfe5a4b8298f8ad90f83012af,
title = "Treatment satisfaction of patients with advanced non small cell lung cancer receiving platinum based chemotherapy: Results from a prospective cohort study (personal)",
abstract = "Introduction.In patients with advanced non–small-cell lung cancer, the treatment benefits and risks need to be constantly weighed. We explored patient-reported satisfaction with therapy (SWT) and assessed its value in addition to quality of life (QoL) and adverse events (AEs).Patients and methods.In a prospective multicenter cohort study, patients with stage IIIB/IV non–small-cell lung cancer received platinum-pemetrexed chemotherapy. They completed the World Health Organization Quality of Life-BREF (WHOQoL-BREF) and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) before and during chemotherapy. After the last cycle, patients reported on SWT, expectations of therapy, and feelings about side effects (FSE) using the Cancer Therapy Satisfaction Questionnaire. The explained variance (R2) of QoL after treatment by SWT was calculated. Using multivariable linear regression, we examined the association of SWT with patient- and treatment-related variables, FSE, and AEs.Results.Eighty-nine patients finished 4 cycles of chemotherapy, 65 of whom completed the Cancer Therapy Satisfaction Questionnaire. Fifty-six patients (86.2{\%}) would probably or definitely decide to undergo the same treatment again, regardless of deterioration or improvement in QoL or a high or low frequency of AEs during chemotherapy. The explained variance of QoL by SWT was greatest for the EORTC QLQ C-30 global health status/QoL scale (R2 = 0.170). Patient age (β = 0.43; 95{\%} confidence interval [CI], 0.05-0.82), FSE (β = 0.17; 95{\%} CI, 0.06-0.29), and tumor response (β = 7.93; 95{\%} CI (1.64 to 14.22)) were independently associated with SWT.Conclusion.SWT could provide important supplementary information in addition to QoL assessments and treatment toxicities. Tumor response, older age, and FSE score were associated with better SWT. These insights could affect decision-making during palliative chemotherapy",
keywords = "BREAST-CANCER, CTSQ, MAINTENANCE THERAPY, NSCLC, PATIENTS ATTITUDES, PATIENTS PREFERENCES, PEMETREXED PLUS CISPLATIN, PHASE-III, PLACEBO PLUS, Palliative chemotherapy, QUALITY-OF-LIFE, Quality of life, SUPPORTIVE CARE, Satisfaction with therapy, TRIAL",
author = "Sabine Visser and {De Mol}, Mark and Kiki Cheung and {Van Toor}, {Jermo J.} and {Van Walree}, {Nico C.} and Stricker, {Bruno H.} and {den Oudsten}, B.L.. and Aerts, {Joachim G.j.v.}",
year = "2018",
doi = "10.1016/j.cllc.2018.03.003",
language = "English",
volume = "19",
pages = "e503--e516",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",
number = "4",

}

Treatment satisfaction of patients with advanced non small cell lung cancer receiving platinum based chemotherapy : Results from a prospective cohort study (personal). / Visser, Sabine; De Mol, Mark; Cheung, Kiki; Van Toor, Jermo J.; Van Walree, Nico C.; Stricker, Bruno H.; den Oudsten, B.L..; Aerts, Joachim G.j.v.

In: Clinical Lung Cancer, Vol. 19, No. 4, 2018, p. e503-e516.

Research output: Contribution to journalArticleScientificpeer-review

TY - JOUR

T1 - Treatment satisfaction of patients with advanced non small cell lung cancer receiving platinum based chemotherapy

T2 - Results from a prospective cohort study (personal)

AU - Visser, Sabine

AU - De Mol, Mark

AU - Cheung, Kiki

AU - Van Toor, Jermo J.

AU - Van Walree, Nico C.

AU - Stricker, Bruno H.

AU - den Oudsten, B.L..

AU - Aerts, Joachim G.j.v.

PY - 2018

Y1 - 2018

N2 - Introduction.In patients with advanced non–small-cell lung cancer, the treatment benefits and risks need to be constantly weighed. We explored patient-reported satisfaction with therapy (SWT) and assessed its value in addition to quality of life (QoL) and adverse events (AEs).Patients and methods.In a prospective multicenter cohort study, patients with stage IIIB/IV non–small-cell lung cancer received platinum-pemetrexed chemotherapy. They completed the World Health Organization Quality of Life-BREF (WHOQoL-BREF) and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) before and during chemotherapy. After the last cycle, patients reported on SWT, expectations of therapy, and feelings about side effects (FSE) using the Cancer Therapy Satisfaction Questionnaire. The explained variance (R2) of QoL after treatment by SWT was calculated. Using multivariable linear regression, we examined the association of SWT with patient- and treatment-related variables, FSE, and AEs.Results.Eighty-nine patients finished 4 cycles of chemotherapy, 65 of whom completed the Cancer Therapy Satisfaction Questionnaire. Fifty-six patients (86.2%) would probably or definitely decide to undergo the same treatment again, regardless of deterioration or improvement in QoL or a high or low frequency of AEs during chemotherapy. The explained variance of QoL by SWT was greatest for the EORTC QLQ C-30 global health status/QoL scale (R2 = 0.170). Patient age (β = 0.43; 95% confidence interval [CI], 0.05-0.82), FSE (β = 0.17; 95% CI, 0.06-0.29), and tumor response (β = 7.93; 95% CI (1.64 to 14.22)) were independently associated with SWT.Conclusion.SWT could provide important supplementary information in addition to QoL assessments and treatment toxicities. Tumor response, older age, and FSE score were associated with better SWT. These insights could affect decision-making during palliative chemotherapy

AB - Introduction.In patients with advanced non–small-cell lung cancer, the treatment benefits and risks need to be constantly weighed. We explored patient-reported satisfaction with therapy (SWT) and assessed its value in addition to quality of life (QoL) and adverse events (AEs).Patients and methods.In a prospective multicenter cohort study, patients with stage IIIB/IV non–small-cell lung cancer received platinum-pemetrexed chemotherapy. They completed the World Health Organization Quality of Life-BREF (WHOQoL-BREF) and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) before and during chemotherapy. After the last cycle, patients reported on SWT, expectations of therapy, and feelings about side effects (FSE) using the Cancer Therapy Satisfaction Questionnaire. The explained variance (R2) of QoL after treatment by SWT was calculated. Using multivariable linear regression, we examined the association of SWT with patient- and treatment-related variables, FSE, and AEs.Results.Eighty-nine patients finished 4 cycles of chemotherapy, 65 of whom completed the Cancer Therapy Satisfaction Questionnaire. Fifty-six patients (86.2%) would probably or definitely decide to undergo the same treatment again, regardless of deterioration or improvement in QoL or a high or low frequency of AEs during chemotherapy. The explained variance of QoL by SWT was greatest for the EORTC QLQ C-30 global health status/QoL scale (R2 = 0.170). Patient age (β = 0.43; 95% confidence interval [CI], 0.05-0.82), FSE (β = 0.17; 95% CI, 0.06-0.29), and tumor response (β = 7.93; 95% CI (1.64 to 14.22)) were independently associated with SWT.Conclusion.SWT could provide important supplementary information in addition to QoL assessments and treatment toxicities. Tumor response, older age, and FSE score were associated with better SWT. These insights could affect decision-making during palliative chemotherapy

KW - BREAST-CANCER

KW - CTSQ

KW - MAINTENANCE THERAPY

KW - NSCLC

KW - PATIENTS ATTITUDES

KW - PATIENTS PREFERENCES

KW - PEMETREXED PLUS CISPLATIN

KW - PHASE-III

KW - PLACEBO PLUS

KW - Palliative chemotherapy

KW - QUALITY-OF-LIFE

KW - Quality of life

KW - SUPPORTIVE CARE

KW - Satisfaction with therapy

KW - TRIAL

U2 - 10.1016/j.cllc.2018.03.003

DO - 10.1016/j.cllc.2018.03.003

M3 - Article

VL - 19

SP - e503-e516

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - 4

ER -